Sandostatin — CareFirst (Caremark)
Neuroendocrine tumors (NETs) including GI tract, lung, thymus (carcinoid tumors)
Reauthorization criteria
- Member is experiencing clinical benefit as evidenced by improvement or stabilization in clinical signs and symptoms since initiation of therapy
Approval duration
12 months